A Phase 2 interventional study of Metformin and Placebo in Polycystic Kidney, Autosomal Dominant, sponsored by Kyongtae Ty Bae, M.D., Ph.D.. Completed at 2 sites in United States. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2022-08-09.
Sponsored by Kyongtae Ty Bae, M.D., Ph.D. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 85 studies in Polycystic Kidney, Autosomal Dominant with a site in United States — 14 open to participants now, 25 under way, 1 of them phase 3. Polycystic Kidney, Autosomal Dominant · United States.
Among the 85 studies in Polycystic Kidney, Autosomal Dominant with a site in United States, this one is the 21st largest by enrollment of the 63 interventional ones that give a count, is one of 3 that started in 2016, is one of 18 in phase 2, and was the 34th registered.
185 studies on the registry are indexed under Polycystic Kidney, Autosomal Dominant; 42 are open to participants now.
Browse Polycystic Kidney, Autosomal Dominant studies →14 of the 85 studies in Polycystic Kidney, Autosomal Dominant with a site in United States are open now. Recruiting first, the newest first:
Vertex Pharmaceuticals Incorporated · Sites in United States
Ages 19–55 · Men only · Healthy volunteers
Kenneth Hallows · Sites in United States
Ages 18–60
Mayo Clinic · Sites in United States
Ages 18–70
Richard Fatica · Sites in United States
Ages 18+
AstraZeneca · Sites in United States, China, United Kingdom
Ages 18–65
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 30 Polycystic Kidney, Autosomal Dominant studies recruiting now, 8 (27%) set no upper age limit and 19 (63%) stop at 75 or younger; 7 take children under 18; 9 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
85 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 25 · Phase 3 18 · Phase 4 2
First in 1998; this study’s year is marked. 3 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 97 is above the median of 51 across 138 interventional studies indexed under Polycystic Kidney, Autosomal Dominant.
Median enrollment 48 across the 63 interventional studies, 90 across the 22 observational. Of the 59 that completed or were terminated, 34 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
34 of 85 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Kyongtae Ty Bae, M.D., Ph.D. as lead sponsor.
Kyongtae Ty Bae, M.D., Ph.D. has 1 study filed under Polycystic Kidney, Autosomal Dominant — fewer than ten, so there is no comparison to draw.
16 of the studies in Polycystic Kidney, Autosomal Dominant with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05193981Mayo ClinicA Study to Evaluate Homocysteine Metabolism and Endothelial Function in ADPKD | 2026-12 |
| NCT05288998Mayo ClinicIntrarenal Microvasculature in ADPKD | 2026-12 |
| NCT06786260Loma Linda UniversityDi-PKD: A Pilot Trial of Dietary Intervention in Patients With Autosomal Dominant Polycystic Kidney Disease | 2026-12 |
| NCT04344769Mayo ClinicCharacterization of the Nrf2 Response in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) | 2026-12 |
| NCT04630613Mayo ClinicNOX4 and Related Biomarkers in ADPKD | 2026-12 |
Add all 16 to your calendar (.ics) → With an account.
Among the 85 studies in Polycystic Kidney, Autosomal Dominant with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will test to see if metformin is safe and if it is tolerated compared to placebo in adult Autosomal Dominant Polycystic Kidney Disease (ADPKD) patients with beginning stages of chronic kidney disease. We will also measure its effect on progression of kidney disease as reflected in the kidney size and the kidney function, along with its effect on kidney pain and quality of life.
There is growing evidence that metformin, a drug widely used for the treatment of type 2 diabetes and polycystic ovary syndrome, may serve as a novel therapy for individuals in the early stages of Autosomal Dominant Polycystic Kidney Disease ADPKD by activating the metabolic sensor AMP-activated protein kinase (AMPK). AMPK is activated under conditions of metabolic and other cellular stresses. Through its actions on downstream mediators, AMPK activation during low energy states decreases cellular energy consumption while stimulating energy generating pathways. It has been shown that AMPK phosphorylates and inhibits cystic fibrosis transmembrane conductance regulator (CFTR), thus suppressing epithelial fluid and electrolyte secretion. Similarly, AMPK phosphorylates the tuberin protein, leading to indirect inhibition of the mTOR pathway. Thus, AMPK inhibits both CFTR and mTOR, suggesting that targeted activation of this kinase by metformin may provide a therapeutic benefit in ADPKD. It has been shown that metformin treatment of kidney epithelial cells leads to stimulation of AMPK and subsequent inhibition of both mTOR and CFTR activity. It has also been shown that metformin slows cystogenesis in animal models of PKD, supporting the potential of this drug in ADPKD treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subject has Autosomal Dominant Polycystic Kidney Disease; Subject is fluent in English
Exclusion Criteria:
Subject is not on active military duty; Subject is not currently participating in another clinical trial; Subject's current is not \<50 cc/min/1.73m2; Subject does not have diabetes; Subject does not have a systemic disease other than hypertension and PKD; Subject does not have a solitary kidney; Subject does not have an allergy or intolerance to metformin; Subject is not pregnant or lactating or intending to become pregnant within the next three years; Subject does not have an unstable or unclipped cerebral aneurysm; Subject does not have active coronary artery disease; Subject does not have an MRI incompatible device/implant; Subject does not have severe claustrophobia; Subject has not had any solid organ transplant; Subject does not have a Vitamin B12 deficiency; Subject does not currently take any medications that interact with metformin, such as nifedipine, furosemide, cationic drugs (amiloride, ranitidine, triamterene digoxin, procainamide, quinidine, vancomycin, trimethoprim); Subject does not currently take nor has taken (within 2 weeks) the drug tolvaptan (Jynarque or Samsca)
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will be started on 500 mg of metformin once daily, with the following scheduled dose titrations: * Increase to 500mg twice daily at week 2 * Increase to 1000mg qAM, 500mg qPM at week 4 * Increase to 1000mg twice daily at week 6 for the duration of their participation (26 months). * Increased titrations based on tolerability
Drug: Metformin
Participants will be started on 500 mg of placebo once daily, with the following scheduled dose titrations: * Increase to 500mg twice daily at week 2 * Increase to 1000mg qAM, 500mg qPM at week 4 * Increase to 1000mg twice daily at week 6 for the duration of their participation (26 months). * Increased titrations based on tolerability
Other: Placebo
Monitoring of tolerability and symptoms.
Also known as: Glucophage, Metformin hydrochloride
Monitoring of tolerability and symptoms.
Change in the Gastrointestinal Symptoms Rating Scale (GSRS) to 24 Months
GSRS is a widely used, validated 15-item questionnaire used to assess GI symptom burden (minimum, maximum: 1, 7, where higher mean score is worse outcome). Mean change to 24 months, estimated with a repeated measures analysis (baseline, 2 weeks, 6 weeks, 1 month, 3 months and every 3 months thereafter to 24 months) using a linear mixed model.
Time frame: Baseline, 2 weeks, 6 weeks, 1 month, 3 months and every 3 months thereafter to 24 months
Drug Tolerability
Tolerability was based on the first visit a participant responded no to the following question "Can you tolerate this dose of study drug the rest of your life?", which was asked at baseline, 2 weeks, 6 weeks, 1 month, 3 months and every 3 months thereafter to 24 months.
Time frame: Baseline, 2 weeks, 6 weeks, 1 month, 3 months and every 3 months thereafter to 24 months
Rate of Serious Adverse Events (SAE)
Serious adverse events (SAE) occurring from the time a participant signs the informed consent (at the screening visit) until the end of the study, meeting 1 or more of the criteria of: 1) Resulting in death, 2) Non-elective hospitalization, 3) Life threatening (if patient continued on study drug would result in death), 4) Harming or disabling persistently or permanently , 5) Exceeding the nature, severity or frequency of risk described in the protocol or 6) Resulting in congenital anomaly.
Time frame: 26 months
Quality of Life Physical Component
Short Form-36 Quality of Life Physical Component Summary (SF-36 PCS) ranges from 0 (worst possible outcome) to 100 (best possible outcome). Mean change to 24 months, estimated with a repeated measures analysis (baseline, 1 month, 3 months and every 3 months thereafter to 24 months) using a linear mixed model.
Time frame: Baseline, 1 month, 3 months and every 3 months thereafter to 24 months
Quality of Life Mental Component
Short Form-36 Quality of Life Mental Component Summary (SF-36 MCS) ranges from 0 (worst possible outcome) to 100 (best possible outcome). Mean change to 24 months, estimated with a repeated measures analysis (baseline, 1 month, 3 months and every 3 months thereafter to 24 months) using a linear mixed model.
Time frame: Baseline, 1 month, 3 months and every 3 months thereafter to 24 months
Back Pain Frequency Over the Past 3 Months Since Last Visit
Odds ratio (OR) per month of back pain Often, Usually, or Always (vs. Never, Rarely, Sometimes) estimated with a repeated measures analysis (baseline, 1 month, 3 months and every 3 months thereafter to 24 months) using a generalized linear mixed model.
Time frame: Baseline, 1 month, 3 months and every 3 months thereafter to 24 months
Estimated Glomerular Filtration Rate (eGFR)
Mean change to 24 months, estimated with a repeated measures analysis (baseline, 2 weeks, 6 weeks, 1 month, 3 months and every 3 months thereafter to 24 months) using a linear mixed model.
Time frame: Baseline, 2 weeks, and 6 weeks, 1 month, 3 months and every 3 months thereafter to 24 months
Total Kidney Volume From Magnetic Resonance Imaging
Annual percent change of height adjusted and natural log transformed total kidney volume \[ln(htTKV)\] was estimated with a linear mixed model.
Time frame: Baseline, 6 months, 12 months, 18 months, 24 months
Total Kidney Cyst Volume From Magnetic Resonance Imaging
Annual percent change of height adjusted and natural log transformed total kidney cyst volume \[ln(htTKCV)\] was estimated with a linear mixed model.
Time frame: Baseline, 6 months, 12 months, 18 months, 24 months
Liver Volume From Magnetic Resonance Imaging
Annual percent change of height adjusted and natural log transformed liver volume \[ln(htLV)\] was estimated with a linear mixed model.
Time frame: Baseline, 6 months, 12 months, 18 months, 24 months
Liver Cyst Volume From Magnetic Resonance Imaging
Annual percent change of height adjusted and natural log transformed liver cyst volume \[ln(htLCV)\] was estimated with a linear mixed model.
Time frame: Baseline, 6 months, 12 months, 18 months, 24 months
Frequency Abdominal Fullness Interfered With Ability to Perform Usual Physical Activity Over the Past 3 Months Since Last Visit.
Odds ratio (OR) per month of abdominal fullness interfered Often, Usually, or Always (vs. Never, Rarely, Sometimes) estimated with a repeated measures analysis (baseline, 1 month, 3 months and every 3 months thereafter to 24 months) using a generalized linear mixed model.
Time frame: Baseline, 1 month, 3 months and every 3 months thereafter to 24 months
Interference of Pain With Sleep Over the Past 3 Months Since Last Visit
Odds ratio (OR) per month of pain interfered with sleep Quite a bit or Extremely (vs. Not at all, A little bit, Moderately) estimated with a repeated measures analysis (baseline, 1 month, 3 months and every 3 months thereafter to 24 months) using a generalized linear mixed model.
Time frame: Baseline, 1 month, 3 months and every 3 months thereafter to 24 months
Interference of Pain With Strenuous Physical Activity Over the Past 3 Months Since Last Visit
Odds ratio (OR) per month of pain interfered with strenuous physical activity Quite a bit or Extremely (vs. Not at all, A little bit, Moderately) estimated with a repeated measures analysis (baseline, 1 month, 3 months and every 3 months thereafter to 24 months) using a generalized linear mixed model.
Time frame: Baseline, 1 month, 3 months and every 3 months thereafter to 24 months
| Milestone | Metformin | Placebo |
|---|---|---|
| Started | 49 | 48 |
| Completed | 40 | 42 |
| Not completed | 9 | 6 |
| Withdrew: Study burden | 3 | 3 |
| Withdrew: Adverse event | 2 | 1 |
| Withdrew: Unable/unwilling to take study medication | 2 | 1 |
| Withdrew: Began tolvaptan | 1 | 1 |
| Withdrew: Withdrawal by subject | 1 | 0 |
GSRS is a widely used, validated 15-item questionnaire used to assess GI symptom burden (minimum, maximum: 1, 7, where higher mean score is worse outcome). Mean change to 24 months, estimated with a repeated measures analysis (baseline, 2 weeks, 6 weeks, 1 month, 3 months and every 3 months thereafter to 24 months) using a linear mixed model.
| score on a scale | Metformin | Placebo |
|---|---|---|
| Change in the Gastrointestinal Symptoms Rating Scale (GSRS) to 24 Months | -0.04 (-0.18 to 0.10) | -0.11 (-0.24 to 0.03) |
Tolerability was based on the first visit a participant responded no to the following question "Can you tolerate this dose of study drug the rest of your life?", which was asked at baseline, 2 weeks, 6 weeks, 1 month, 3 months and every 3 months thereafter to 24 months.
| Participants | Metformin | Placebo |
|---|---|---|
| Drug Tolerability | 21 | 14 |
Serious adverse events (SAE) occurring from the time a participant signs the informed consent (at the screening visit) until the end of the study, meeting 1 or more of the criteria of: 1) Resulting in death, 2) Non-elective hospitalization, 3) Life threatening (if patient continued on study drug would result in death), 4) Harming or disabling persistently or permanently , 5) Exceeding the nature, severity or frequency of risk described in the protocol or 6) Resulting in congenital anomaly.
| Participants | Metformin | Placebo |
|---|---|---|
| Rate of Serious Adverse Events (SAE) | 4 | 4 |
Short Form-36 Quality of Life Physical Component Summary (SF-36 PCS) ranges from 0 (worst possible outcome) to 100 (best possible outcome). Mean change to 24 months, estimated with a repeated measures analysis (baseline, 1 month, 3 months and every 3 months thereafter to 24 months) using a linear mixed model.
| score on a scale | Metformin | Placebo |
|---|---|---|
| Quality of Life Physical Component | -0.11 (-1.69 to 1.46) | -0.51 (-2.05 to 1.03) |
Short Form-36 Quality of Life Mental Component Summary (SF-36 MCS) ranges from 0 (worst possible outcome) to 100 (best possible outcome). Mean change to 24 months, estimated with a repeated measures analysis (baseline, 1 month, 3 months and every 3 months thereafter to 24 months) using a linear mixed model.
| score on a scale | Metformin | Placebo |
|---|---|---|
| Quality of Life Mental Component | 1.01 (-1.23 to 3.25) | -0.11 (-2.29 to 2.08) |
Odds ratio (OR) per month of back pain Often, Usually, or Always (vs. Never, Rarely, Sometimes) estimated with a repeated measures analysis (baseline, 1 month, 3 months and every 3 months thereafter to 24 months) using a generalized linear mixed model.
| odds ratio | Metformin | Placebo |
|---|---|---|
| Back Pain Frequency Over the Past 3 Months Since Last Visit | 0.95 (0.90 to 1.00) | 0.92 (0.88 to 0.98) |
Mean change to 24 months, estimated with a repeated measures analysis (baseline, 2 weeks, 6 weeks, 1 month, 3 months and every 3 months thereafter to 24 months) using a linear mixed model.
| ml/min/1.73m^2 | Metformin | Placebo |
|---|---|---|
| Estimated Glomerular Filtration Rate (eGFR) | -3.41 (-6.36 to -0.46) | -6.14 (-9.04 to -3.24) |
Annual percent change of height adjusted and natural log transformed total kidney volume \[ln(htTKV)\] was estimated with a linear mixed model.
| annual percent change | Metformin | Placebo |
|---|---|---|
| Total Kidney Volume From Magnetic Resonance Imaging | 3.87 (1.09 to 6.74) | 2.16 (-0.52 to 4.91) |
Annual percent change of height adjusted and natural log transformed total kidney cyst volume \[ln(htTKCV)\] was estimated with a linear mixed model.
| annual percent change | Metformin | Placebo |
|---|---|---|
| Total Kidney Cyst Volume From Magnetic Resonance Imaging | 9.37 (3.82 to 15.22) | 5.36 (0.13 to 10.86) |
Annual percent change of height adjusted and natural log transformed liver volume \[ln(htLV)\] was estimated with a linear mixed model.
| annual percent change | Metformin | Placebo |
|---|---|---|
| Liver Volume From Magnetic Resonance Imaging | 1.60 (0.02 to 3.21) | 1.21 (-0.32 to 2.77) |
Annual percent change of height adjusted and natural log transformed liver cyst volume \[ln(htLCV)\] was estimated with a linear mixed model.
| annual percent change | Metformin | Placebo |
|---|---|---|
| Liver Cyst Volume From Magnetic Resonance Imaging | 12.72 (3.47 to 22.79) | 10.94 (1.73 to 20.99) |
Odds ratio (OR) per month of abdominal fullness interfered Often, Usually, or Always (vs. Never, Rarely, Sometimes) estimated with a repeated measures analysis (baseline, 1 month, 3 months and every 3 months thereafter to 24 months) using a generalized linear mixed model.
| odds ratio | Metformin | Placebo |
|---|---|---|
| Frequency Abdominal Fullness Interfered With Ability to Perform Usual Physical Activity Over the Past 3 Months Since Last Visit. | 1.00 (0.89 to 1.13) | 0.99 (0.87 to 1.12) |
Odds ratio (OR) per month of pain interfered with sleep Quite a bit or Extremely (vs. Not at all, A little bit, Moderately) estimated with a repeated measures analysis (baseline, 1 month, 3 months and every 3 months thereafter to 24 months) using a generalized linear mixed model.
| odds ratio | Metformin | Placebo |
|---|---|---|
| Interference of Pain With Sleep Over the Past 3 Months Since Last Visit | 1.00 (0.87 to 1.14) | 0.97 (0.88 to 1.07) |
Odds ratio (OR) per month of pain interfered with strenuous physical activity Quite a bit or Extremely (vs. Not at all, A little bit, Moderately) estimated with a repeated measures analysis (baseline, 1 month, 3 months and every 3 months thereafter to 24 months) using a generalized linear mixed model.
| odds ratio | Metformin | Placebo |
|---|---|---|
| Interference of Pain With Strenuous Physical Activity Over the Past 3 Months Since Last Visit | 0.99 (0.93 to 1.06) | 0.95 (0.90 to 1.01) |
Collected over Adverse event were data collected at 2, 4, and 6 weeks during the titration period and every 3 months thereafter through 26 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Metformin | 0/49 (0%) | 4/49 (8.2%) | 21/49 (42.9%) |
| Placebo | 0/48 (0%) | 4/48 (8.3%) | 13/48 (27.1%) |
| Event | Metformin | Placebo |
|---|---|---|
| Other - lightheadednessNervous system disorders | 0/49 | 1/48 |
| Appendicitis perforatedInfections and infestations | 0/49 | 1/48 |
| Other - urinary tract infection and renal cyst hemorrhage (mild)Infections and infestations | 0/49 | 1/48 |
| Other - renal cystRenal and urinary disorders | 0/49 | 1/48 |
| Other - renal cyst ruptureRenal and urinary disorders | 0/49 | 1/48 |
| Other - diarrhea (c. difficile infection)Infections and infestations | 1/49 | 0/48 |
| Other - bone fractureMusculoskeletal and connective tissue disorders | 1/49 | 0/48 |
| SeizureNervous system disorders | 1/49 | 0/48 |
| Gastric hemorrhageGastrointestinal disorders | 1/49 | 0/48 |
| Suicide attemptPsychiatric disorders | 1/49 | 0/48 |
| Event | Metformin | Placebo |
|---|---|---|
| DiarrheaGastrointestinal disorders | 21/49 | 13/48 |
| NauseaGastrointestinal disorders | 17/49 | 10/48 |
| FlatulenceGastrointestinal disorders | 10/49 | 7/48 |
| Abdominal PainGastrointestinal disorders | 8/49 | 9/48 |
| CoughRespiratory, thoracic and mediastinal disorders | 5/49 | 9/48 |
| HeadacheNervous system disorders | 8/49 | 6/48 |
| ConstipationGastrointestinal disorders | 6/49 | 7/48 |
| Sore ThroatRespiratory, thoracic and mediastinal disorders | 5/49 | 7/48 |
| Abdominal DistensionGastrointestinal disorders | 7/49 | 4/48 |
| VomitingGastrointestinal disorders | 5/49 | 6/48 |
| Age, Categorical(Participants) | Metformin | Placebo | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 49 | 48 | 97 |
| >=65 years | 0 | 0 | 0 |
| Age, Continuous(years) | Metformin | Placebo | Total |
|---|---|---|---|
| Mean | 41.8 ± 10.4 | 42.1 ± 10.1 | 41.9 ± 10.2 |
| Sex: Female, Male(Participants) | Metformin | Placebo | Total |
|---|---|---|---|
| Female | 38 | 32 | 70 |
| Male | 11 | 16 | 27 |
| Ethnicity (NIH/OMB)(Participants) | Metformin | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 2 | 6 | 8 |
| Not Hispanic or Latino | 47 | 42 | 89 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Metformin | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 |
| Asian | 2 | 1 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 1 |
| White | 46 | 46 | 92 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | Metformin | Placebo | Total |
|---|---|---|---|
| United States | 49 | 48 | 97 |
| PKD genotype(Participants) | Metformin | Placebo | Total |
|---|---|---|---|
| PKD1 | 37 | 28 | 65 |
| PKD2 | 7 | 10 | 17 |
| Other | 1 | 4 | 5 |
| No mutation detected | 2 | 4 | 6 |
| N/A | 2 | 2 | 4 |
| GFR((ml/min/1.73 m²)) | Metformin | Placebo | Total |
|---|---|---|---|
| Mean | 86.1 ± 20.6 | 85.9 ± 19.0 | 86.0 ± 19.7 |
14 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jun 2016 to primary completion in Dec 2020, 53 months.
Results were first posted in Aug 2022, 1 year 8 months after primary completion.
Of 17 phase 2 interventional studies under Polycystic Kidney, Autosomal Dominant, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 53. This study's 53 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Metformin
Polycystic Kidney, Autosomal Dominant →